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Binding of foot-and-mouth disease virus (FMDV) to cells requires an arginine-glycine-aspartic acid (RGD)
sequence in the capsid protein VP1. We have genetically engineered an FMDV in which these three amino acids have been deleted, producing a virus particle which is unable to bind to cells. Cattle vaccinated with these receptor binding site-deleted virions were protected from disease when challenged with a virulent virus, demonstrating that these RGD-deleted viruses could serve as the basis for foot-and-mouth disease vaccines safer than those currently in use. This strategy may prove useful in the development of vaccines for other viral diseases.
Foot-and-mouth disease virus (FMDV), which comprises the Aphthovirus genus of the family Picornaviridae, causes a devastating disease of livestock (2, 18) . The virion consists of a single-strand, positive-sense RNA genome packaged in an icosahedrally symmetric shell composed of 60 copies each of four structural proteins, VP1 to VP4. Chemically inactivated vaccines have been widely used to control foot-and-mouth disease (FMD), but frequent revaccination is required to maintain protective immunity (2, 18) . Furthermore, the presence of residual live viruses in these inactivated vaccines and the escape of viruses from vaccine production plants have been implicated in FMD outbreaks (8) . Here, we describe the use of a genetically inactivated FMDV as an effective vaccine.
The three-dimensional structure of FMDV has revealed a prominent surface feature formed by the loop between the G and H ␤ strands of VP1 (referred to herein as the G-H loop) that is partially disordered under some conditions (1, 14, 17) . Despite its flexibility, the G-H loop contains a highly conserved arginine-glycine-aspartic acid (RGD) sequence that has been implicated in receptor binding on the basis of synthetic peptide inhibition studies (5, 13) . Using a genetic engineering approach, we confirmed that the RGD sequence is required for binding viruses to host cells by demonstrating that viruses with amino acid substitutions within the RGD sequence were unable to bind to or infect cells (16) . However, viruses created with a single point mutation in the sequences encoding the RGD segment reverted to virulence by regaining the RGD sequence (16) , consistent with the well-known variability of the FMDV genome (11, 12) .
To create a stable, genetically inactivated FMDV for use as a vaccine, we constructed a virus in which the entire RGD sequence was deleted to prevent reversion to virulence. Specifically, a genome-length cDNA of FMDV type A 12 (20) in which the codons specifying the wild-type amino acid sequence SGSGVRGDFGSL were replaced with codons for SGSNPGSL was engineered, and synthetic RNA transcripts derived from this cDNA were transfected into baby hamster kidney (BHK) cells by electroporation (16) . (The deleted or inserted residues are underlined and in boldface type.) Cells transfected under these conditions produced levels of virus particles similar to those produced by cells transfected with wild-type RNA. Preliminary experiments showed that these particles did not bind to cells, were noninfectious, and were recognized by monoclonal antibodies representing four different epitopes of FMDV type A 12 (6, 7) . Interestingly, one of these epitopes includes portions of the G-H loop (7), indicating that this deletion had little, if any, effect on the antigenic structure of the RGDdeleted virus.
By expanding our previously published electroporation methods (16), we produced large numbers of cells transfected with the RGD-deleted RNA. The virus particles present in the culture fluid harvested from these cells were concentrated by polyethylene glycol precipitation and further purified by sucrose density gradient centrifugation (6, 16) . The amount of virus present in these partially purified preparations was estimated from VP2 protein content on Western blots (immunoblots) (21) . Western blots were generated with four twofold dilutions of wild-type virus quantitated by UV absorbance measurements (3) and developed by using polyclonal guinea pig serum specific for FMDV and 125 I-labeled protein A (New England Nuclear, Boston, Mass.). The density of the band for VP2, which was not altered in the receptor binding site-deleted virus, was quantitated in each sample by using Molecular Dynamics ImageQuant version 3.15 software. The VP2 normogram generated from the wild-type virus dilutions was used to establish the amount of virus present in the RGD-deleted virus preparation analyzed in the same Western blot. These experiments revealed that under conditions in which saturating amounts of RNA were used (16) Either wild-type or RGD-deleted virus (2 g) was inoculated into the coronary band and the dermis of the snout of one of two adult Yorkshire swine. The animals were observed for signs of FMD for 2 weeks. The animal that received 2 g of wild-type virus developed classical FMD (fever and lameness with vesicles on all four feet and the snout) within 5 days of inoculation, whereas the animal inoculated with 2 g of the RGD-deleted virus did not show any signs of disease. As expected, radioimmunoprecipitation analyses of serum collected 28 days postinfection from the animal inoculated with the wild-type virus revealed strong reactivity to structural proteins and the nonstructural proteins 3D, 3AB, and 2C, indicating that the wild-type virus had replicated in the animal (9, 15) . In contrast, the 28-day postinoculation serum obtained from the pig inoculated by this route with the RGD-deleted virus showed very low levels of reactivity with structural proteins and no detectable reactivity with nonstructural proteins (results not shown), indicating that the RGD-deleted virus did not replicate in this animal (9, 15) . To test the usefulness of the RGD-deleted virus as a vaccine, we conducted a vaccination challenge study with nine 18-to 20-month-old Hereford steers. Three steers were vaccinated intramuscularly with a tissue culture medium-mineral oil (9:1 Marcol 52/Montanide 888) emulsion (mock vaccine), three animals were vaccinated intramuscularly with 2 g of sucrose gradient-purified, binary ethylenimine (BEI)-inactivated (4) wild-type virus emulsified in oil, and the remaining three animals were vaccinated intramuscularly with an oil emulsion containing 2 g of the RGD-deleted virus. Animals were observed for signs of FMD for 4 weeks. None of the animals developed fever or vesicles, classic signs of FMD. Four weeks postvaccination, serum samples were collected from all nine animals and tested for their ability to neutralize the virus in vitro. Table 1 shows that the RGD-deleted and the BEI-inactivated vaccines generated similar serum neutralization titers in steers, whereas the mock-vaccinated steers did not show any response to FMDV. These results indicate that the two vaccines performed equally well in their ability to elicit neutralizing antibodies in cattle at the dose tested.
The nine animals listed in Table 1 were combined in a single large room and exposed to a pig which had developed severe clinical manifestations of FMD after infection with a virulent cattle-passaged strain of FMDV type A 12 (Vallee strain 119, cattle passage 78 [10] , kindly provided by J. House). The cattle were examined daily for the onset of clinical signs (lameness, vesicle formation on the tongue, or fever). If temperatures over 39ЊC were noted, the animals were sedated and examined closely for vesicular lesions on their feet and in their oral cavities. All six vaccinated animals were protected from clinical disease, whereas all three mock-vaccinated animals demonstrated clinical FMD within 7 days of exposure to the infected pig, with temperatures over 40ЊC for 3 days (Fig. 1) and lesions on the tongue and all four feet.
The effectiveness of the vaccine was further evaluated by determining if viral challenge had produced immune responses to viral antigens by comparison of the abilities of pre-and postchallenge sera to precipitate viral proteins from radiolabeled infected cell lysates (Fig. 2) . For one animal (animal 143), a weak reaction to 3D was observed in prechallenge serum, consistent with the fact that antibodies to 3D are often observed in sera from vaccinated animals (9, 15) . Figure 2 also shows that antibodies to nonstructural proteins 2C, 3AB, and 3C were present in postchallenge sera of mock-vaccinated animals. On the basis of previously established criteria (9, 15) , the presence of antibodies to two or more of these antigens demonstrates extensive viral replication, consistent with the observed clinical signs in these animals ( Table 1 ; Fig. 1 ). Several minor differences between pre-and postchallenge sera were also noted among the six vaccinated animals, and in several cases antibodies to 3D were detected in postchallenge serum samples. However, following challenge none of the vaccinated animals developed antibodies to 2C, 3AB, or 3C (Fig. 2 ), indicating that vaccination had prevented, or severely limited, viral replication (9, 15) . Interestingly, one of the BEI-inactivated vaccine-vaccinated animals (animal 101) showed an increase in antibodies to structural proteins and the appearance of reactivity with 3D after challenge (Fig. 2) , suggesting that limited, but clearly detectable, viral replication had taken place in the face of challenge in this animal. The possibility that virus replication occurred in this animal is consistent with the finding that this animal showed the lowest prechallenge titer of neutralizing antibodies (Table 1) .
This study demonstrates that the RGD-deleted vaccine performed as well as, or exceeded, the accepted BEI-inactivated vaccine with respect to protection from challenge, generation of serum-neutralizing antibodies, and generation of an immune response which restricts replication of the virus upon challenge. This is the first demonstration that a safe and effective vaccine can be prepared by genetically removing the cell binding site from a virus.
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FIG. 2.
Comparison of the abilities of prechallenge and postchallenge sera to immunoprecipitate proteins from FMDV-infected cells. Serum samples were collected from the indicated animals at 28 days following vaccination (Pre); the animals were challenged the next day, and a second serum sample was collected from each animal 28 days later (Post). Lane 1, convalescent serum (Conv). Serum samples were reacted with radiolabeled lysates of virus-infected cells, and immune complexes were precipitated and analyzed as described previously (19) . The positions of the viral proteins are listed on the left-hand side of the autoradiogram.
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